Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 30

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials

Jaiswal, Vikash, Sawhney, Aanchal, Nebuwa, Chikodili, Borra, Vamsikalyan, Deb, Novonil, Halder, Anupam, Rajak, Kripa, Jha, Mayank, Wajid, Zarghoona, Thachil, Rosy, Bandyopadhyay, Dhrubajyoti, Mattumpuram, Jishanth, Lavie, Carl J. · 2024 · Progress in Cardiovascular Diseases

Abstract

BACKGROUND The Cardiovascular safety of testosterone replacement therapy (TRT) among men with hypogonadism is not well established to date. Hence, we sought to evaluate the cardiovascular disease (CVD) outcomes among patients receiving testosterone therapy by using all recently published randomized controlled trials. METHODS We performed a systematic literature search on PubMed, EMBASE, and Clinicaltrial.gov for relevant randomized controlled trials (RCTs) from inception until September 30th, 2023. RESULTS A total of 30 randomized trials with 11,502 patients were included in the final analysis. The mean age was ranging from 61.61 to 61.82 years. Pooled analysis of primary and secondary outcomes showed that the incidence of any CVD events (OR, 1.12 (95%CI: 0.77-1.62), P = 0.55), stroke (OR, 1.01 (95%CI: 0.68-1.51), P = 0.94), myocardial infarction (OR, 1.05 (95%CI: 0.76-1.45), P = 0.77), all-cause mortality (OR, 0.94 (95%CI: 0.76-1.17), P = 0.57), and CVD mortality (OR, 0.87 (95%CI: 0.65-1.15), P = 0.31) was comparable between TRT and placebo groups. CONCLUSION Our analysis indicates that for patients with hypogonadism, testosterone replacement therapy does not increase the CVD risk and all-cause mortality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pcad.2024.04.001

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 43

  1. Hagi, 2021, Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia: a systematic review and Meta-analysis, JAMA Psychiatry, 78, 510, 10.1001/jamapsychiatry.2021.0015 · DOI · Paper page
  2. Kloner, 2016, Testosterone and cardiovascular disease, J Am Coll Cardiol, 67, 545, 10.1016/j.jacc.2015.12.005 · DOI · Paper page
  3. Gandaglia, 2014, The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study, BJU Int, 114, E82, 10.1111/bju.12732 · DOI
  4. Alibhai, 2009, Impact of androgen deprivation therapy on cardiovascular disease and diabetes, J Clin Oncol Off J Am Soc Clin Oncol, 27, 3452, 10.1200/JCO.2008.20.0923 · DOI · Paper page
  5. Angell, 2012, Anabolic steroids and cardiovascular risk, Sports Med Auckl NZ, 42, 119, 10.2165/11598060-000000000-00000 · DOI
  6. Elagizi, 2018, Testosterone and cardiovascular health, Mayo Clin Proc, 93, 83, 10.1016/j.mayocp.2017.11.006 · DOI
  7. Elagizi, 2024, Testosterone and cardiovascular health, Eur Heart J, 45, 139, 10.1093/eurheartj/ehad513 · DOI
  8. Krishnan, 2024, Testosterone therapy and the risk of cardiovascular disease in older, hypogonadal men, Prog Cardiovasc Dis, 10.1016/j.pcad.2024.02.015 · DOI
  9. Jaiswal, 2024, Association between catheter ablation and dementia among patients with atrial fibrillation: a systematic review and meta-analysis, Curr Probl Cardiol, 49
  10. Jaiswal, 2023, Percutaneous coronary intervention versus coronary artery bypass grafting among patients with left ventricular systolic dysfunction: a systematic review and meta-analysis, Ann Med Surg, 85, 2849, 10.1097/MS9.0000000000000634 · DOI
  11. Jaiswal, 2023, Association between heart failure and incidence of cancer: a systematic review and meta-analysis, J Am Coll Cardiol, 81
  12. Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat Med, 21, 1539, 10.1002/sim.1186 · DOI · Paper page
  13. Lincoff, 2023, Cardiovascular safety of testosterone-replacement therapy, N Engl J Med, 389, 107, 10.1056/NEJMoa2215025 · DOI · Paper page
  14. Malkin, 2006, Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial, Eur Heart J, 27, 57, 10.1093/eurheartj/ehi443 · DOI · Paper page
  15. Kenny, 2010, Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty, J Am Geriatr Soc, 58, 1134, 10.1111/j.1532-5415.2010.02865.x · DOI · Paper page
  16. Snyder, 2001, Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age, Am J Med, 111, 255, 10.1016/S0002-9343(01)00813-0 · DOI
  17. Behre, 2012, Aging Male Off J Int Soc Study Aging Male, 15, 198, 10.3109/13685538.2012.699562 · DOI
  18. Hackett, 2014, The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study), Int J Clin Pract, 68, 203, 10.1111/ijcp.12235 · DOI
  19. Svartberg, 2004, Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial, Respir Med, 98, 906, 10.1016/j.rmed.2004.02.015 · DOI
  20. Amory, 2004, Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone, J Clin Endocrinol Metab, 89, 503, 10.1210/jc.2003-031110 · DOI · Paper page
  21. Gianatti, 2014, Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial, Diabetes Care, 37, 2098, 10.2337/dc13-2845 · DOI · Paper page
  22. Aversa, 2010, Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study, J Sex Med, 7, 3495, 10.1111/j.1743-6109.2010.01931.x · DOI · Paper page
  23. Aversa, 2010, Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome, J Endocrinol Invest, 33, 776, 10.1007/BF03350341 · DOI
  24. Merza, 2006, Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism, Int J Androl, 29, 381, 10.1111/j.1365-2605.2005.00612.x · DOI
  25. Crawford, 2003, Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment, J Clin Endocrinol Metab, 88, 3167, 10.1210/jc.2002-021827 · DOI · Paper page
  26. Barnouin, 2021, Testosterone replacement therapy added to intensive lifestyle intervention in older men with obesity and hypogonadism, J Clin Endocrinol Metab, 106, e1096, 10.1210/clinem/dgaa917 · DOI
  27. Kalinchenko, 2010, Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study, Clin Endocrinol (Oxf), 73, 602, 10.1111/j.1365-2265.2010.03845.x · DOI · Paper page
  28. Kaufman, 2012, One-year efficacy and safety study of a 1.62% testosterone gel in Hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study, J Sex Med, 9, 1149, 10.1111/j.1743-6109.2011.02630.x · DOI
  29. Navarro-Peñalver, 2018, Testosterone replacement therapy in deficient patients with chronic heart failure: a randomized double-blind controlled pilot study, J Cardiovasc Pharmacol Ther, 23, 543, 10.1177/1074248418784020 · DOI
  30. Legros, 2009, Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study, Eur J Endocrinol, 160, 821, 10.1530/EJE-08-0634 · DOI
  31. Morgentaler, 2016, Fundamental concepts regarding testosterone deficiency and treatment: international expert consensus resolutions, Mayo Clin Proc, 91, 881, 10.1016/j.mayocp.2016.04.007 · DOI
  32. Alexander, 2017, Cardiovascular risks of exogenous testosterone use among men: a systematic review and Meta-analysis, Am J Med, 130, 293, 10.1016/j.amjmed.2016.09.017 · DOI
  33. Wallis, 2016, Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study, Lancet Diabetes Endocrinol, 4, 498, 10.1016/S2213-8587(16)00112-1 · DOI · Paper page
  34. Sardar, 2023, Identification of novel biomarkers for early diagnosis of atherosclerosis using high-resolution metabolomics, Metabolites, 13, 1160, 10.3390/metabo13111160 · DOI
  35. Cai, 2014, Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials, Asian J Androl, 16, 146, 10.4103/1008-682X.122346 · DOI
  36. Webb, 2008, Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease, Am J Cardiol, 101, 618, 10.1016/j.amjcard.2007.09.114 · DOI
  37. Gagliano-Jucá, 2017, Effects of testosterone replacement on electrocardiographic parameters in men: findings from two randomized trials, J Clin Endocrinol Metab, 102, 1478, 10.1210/jc.2017-00196 · doi:10.1210/jc.2017-00196
  38. Gagliano-Jucá, 2018, Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer, J Endocr Soc, 2, 485, 10.1210/js.2018-00039 · DOI
  39. Al-Qudimat, 2021, Testosterone treatment improves liver function and reduces cardiovascular risk: a long-term prospective study, Arab J Urol, 19, 376, 10.1080/2090598X.2021.1959261 · DOI
  40. Kaur, 2021, The effect of testosterone on cardiovascular disease and cardiovascular risk factors in men: a review of clinical and preclinical data, CJC Open, 3, 1238, 10.1016/j.cjco.2021.05.007 · DOI
  41. Oh, 2022, Sex hormones and the risk of cardiovascular disease and mortality in male and female patients with chronic kidney disease: a systematic review and meta-analysis, Physiol Rep, 10, 10.14814/phy2.15490 · DOI
  42. Gagliano-Jucá, 2019, Testosterone replacement therapy and cardiovascular risk, Nat Rev Cardiol, 16, 555, 10.1038/s41569-019-0211-4 · DOI · Paper page
  43. Blackwell, 2023, Testosterone replacement therapy and cardiovascular disease: balancing safety and risks in Hypogonadal men, Curr Cardiol Rep, 25, 1157, 10.1007/s11886-023-01935-1 · DOI

Metadata

Authors
Jaiswal, V., Sawhney, A., Nebuwa, C., Borra, V., Deb, N., Halder, A., Rajak, K., Jha, M., Wajid, Z., Thachil, R., Bandyopadhyay, D., Mattumpuram, J., & Lavie, C. J.
Venue
Progress in Cardiovascular Diseases
Publisher
Elsevier BV
Published
2024-07
Volume
85
Pages
45-53
ISSN
0033-0620
Cited by
30
References
24
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials. https://app.cochat.ai/papers/10.1016/j.pcad.2024.04.001
The paper
Jaiswal, V., Sawhney, A., Nebuwa, C., Borra, V., Deb, N., Halder, A., Rajak, K., Jha, M., Wajid, Z., Thachil, R., Bandyopadhyay, D., Mattumpuram, J., & Lavie, C. J. (2024). Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2024.04.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.